MJgraphics / Shutterstock.com
As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.
Biotech multinational AbbVie has long reigned supreme in the biologics marketplace.
But the mastermind of blockbuster drug Humira has come under intense scrutiny of late over its pricing and patent strategies.
Brought to market in 2003, the anti-inflammatory drug has dominated the market for two decades.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Humira, AbbVie, patents, drug pricing, patent walls, biosimilars, biotech, pharma